Media headlines about iCo Therapeutics (OTCMKTS:ICOTF) have trended negative on Wednesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by monitoring more than 6,000 blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iCo Therapeutics earned a news impact score of -2.13 on their scale. InfoTrie also assigned media headlines about the biotechnology company an news buzz score of 8 out of 10, indicating that recent news coverage is very likely to have an effect on the stock’s share price in the near term.
Shares of OTCMKTS ICOTF opened at $0.05 on Wednesday. iCo Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.20.
iCo Therapeutics (OTCMKTS:ICOTF) last issued its quarterly earnings data on Wednesday, August 29th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/28/ico-therapeutics-icotf-receiving-critical-press-coverage-study-finds.html.
About iCo Therapeutics
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
Featured Story: Futures Contract
Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.